An international team of researchers report in the journal Nature Immunology that a mutation in the gene OTULIN causes pediatric-onset pyoderma gangrenosum, characterized by recurrent ulcerating skin ...

The pathogenic mechanisms underlying pyoderma gangrenosum (PG) remain unclear. Here we report three patients with PG from two unrelated kindreds with homozygous R57C mutation of the linear ...

Pyoderma gangrenosum (PG) is a rare, complex, and severe inflammatory dermatosis categorized under the spectrum of neutrophilic dermatoses (NDs), pathologically characterized by sterile neutrophilic ...

Jena, Germany, March 30, 2026 (GLOBE NEWSWIRE)-- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced ...

ABSTRACT: Background and Objectives: Perianal fistulizing Crohn's disease (pCD) is a challenging phenotype, often associated with significant morbidity and reduced quality of life. Follicular ...

Multiple myeloma rarely affects the skin, but it can cause plasmacytoma, ulcers, or bruising. Skin issues may occur when plasma cells build up, abnormal M protein accumulates, or medications irritate ...

PYOGENIC cutaneous infections are commonly seen in the practice of medicine. Often, these conditions are localized to the skin and are not accompanied by constitutional symptoms. One of their ...

Dr Irina Matricoti, Veterinary Surgeon, European Specialist in Veterinary Dermatology The treatment of pyoderma must be differentiated between superficial and surface forms and deep forms. Coccal ...

A systematic review of 63 cases found that pyoderma gangrenosum (PG) during pregnancy or postpartum was often misdiagnosed, delaying treatment and leading to inappropriate interventions. Researchers ...

Canine pyoderma is a common bacterial skin infection predominantly caused by Staphylococcus pseudintermedius. Depending on the depth of infection, pyoderma can be classified as surface, superficial ...

InflaRx N.V. (NASDAQ:IFRX) on Wednesday announced that the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase 3 trial for vilobelimab in pyoderma ...